© Copyright 2009 by the Society for Neuro-Oncology
Received July 28, 2008
Accepted November 30, 2008
Basic and Translational Investigations
|
Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas
Yi Lin 1,
Tao Jiang 2,
Kaijia Zhou 2,
Li Xu 2,
Baoshi Chen 2,
Guilin Li 2,
Xiaoguang Qiu 2,
Tianzi Jiang 3,
Sonya W. Song 3*,
Wei Zhang 4
1 Department of Neurosurgery, Tiantan Hospital, Capital Medical University, Beijing, China; Department of Neurosurgery, the First Affiliated Hospital, China Medical University, Shenyang, China
2 Department of Neurosurgery, Tiantan Hospital, Capital Medical University, Beijing, China
3 LIAMA Center for Computational Medicine, National Laboratory of Pattern Recognition, Institute of Automation, Chinese Academy of Sciences, Beijing, China
4 Department of Pathology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
* To whom correspondence should be addressed. E-mail: weisonyasong{at}gmail.com.
 |
Abstract |
|---|
Insulin-like growth factor binding protein-2 (IGFBP-2) is a malignancy-associated protein measurable in tumor and blood. Increased IGFBP-2 is associated with shortened survival of advanced glioma patients. Thus, we examined plasma IGFBP-2 levels in glioma patients and healthy controls to evaluate its value as a plasma biomarker for glioma. Plasma IGFBP-2 levels in 196 patients with newly diagnosed glioma and 55 healthy controls were analyzed using an IGFBP-2 ELISA kit. Blood was collected before surgery, after 2 cycle-adjuvant chemotherapy and at recurrence. Plasma IGFBP-2 levels were correlated with disease-free survival using Cox regression analyses. We found that preoperative plasma IGFBP-2 levels were significantly higher in high-grade glioma patients (n = 43, 72 for grade III glioma and glioblastoma multiforme [GBM], respectively) than healthy controls (n = 55) (p<0.001) and low-grade (grade II) glioma patients (n = 81) (p<0.001). No significant differences in preoperative plasma IGFBP-2 levels were observed between grade III glioma and GBM patients or between grade II glioma patients and healthy controls. After recurrence, plasma IGFBP-2 levels were significantly increased in GBM patients (n = 26) (p<0.001). Preoperative plasma IGFBP-2 levels were significantly correlated with disease-free survival in GBM patients (hazard ratio, 1.404; 95%CI, 1.078–1.828; p=0.012). We conclude that preoperative plasma IGFBP-2 levels are significantly higher in high-grade glioma patients than in low-grade glioma patients and healthy subjects, and are significantly correlated with recurrence and disease-free survival in patients with GBM. Longitudinal studies with a larger study population are needed to confirm these findings.
Key Words:
glioma, IGFBP-2, plasma surrogate biomarker, prognosis, recurrence
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
